Contrasting activities of estrogen receptor beta isoforms in triple negative breast cancer.

ABSTRACT:

Purpose

Triple negative breast cancer (TNBC), an aggressive subtype of breast cancer, lacks the three major receptors for predicting outcome or targeting therapy. Hence, our aim was to evaluate the potential of estrogen receptor beta (ERβ) as a possible endocrine therapy target in TNBC.

Methods

The expression and prognostic effect of ERβ isoforms were analyzed using TCGA breast tumor data, and the expression of ERβ isoform mRNA and protein in TNBC cell lines was assayed. Endogenous ERβ2 and ERβ5 were knocked down with siRNA, and ERβ2, ERβ5, and ERβ1 were upregulated using a doxycycline-inducible lentiviral system. Cell proliferation, migration and invasion, and specific gene expressions were evaluated.

Results

ERβ2 and ERβ5 were the predominant endogenous forms of ERβ

SUBMITTER: Yan S 

PROVIDER: S-EPMC7867590 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature